» Articles » PMID: 33260345

Peptide-Affinity Precipitation of Extracellular Vesicles and Cell-Free DNA Improves Sequencing Performance for the Detection of Pathogenic Mutations in Lung Cancer Patient Plasma

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2020 Dec 2
PMID 33260345
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Liquid biopsy is a minimally-invasive diagnostic method that may improve access to molecular profiling for non-small cell lung cancer (NSCLC) patients. Although cell-free DNA (cf-DNA) isolation from plasma is the standard liquid biopsy method for detecting DNA mutations in cancer patients, the sensitivity can be highly variable. Vn96 is a peptide with an affinity for both extracellular vesicles (EVs) and circulating cf-DNA. In this study, we evaluated whether peptide-affinity (PA) precipitation of EVs and cf-DNA from NSCLC patient plasma improves the sensitivity of single nucleotide variants (SNVs) detection and compared observed SNVs with those reported in the matched tissue biopsy. NSCLC patient plasma was subjected to either PA precipitation or cell-free methods and total nucleic acid (TNA) was extracted; SNVs were then detected by next-generation sequencing (NGS). PA led to increased recovery of DNA as well as an improvement in NGS sequencing parameters when compared to cf-TNA. Reduced concordance with tissue was observed in PA-TNA (62%) compared to cf-TNA (81%), mainly due to identification of SNVs in PA-TNA that were not observed in tissue. mutations were detected in PA-TNA with 83% sensitivity and 100% specificity. In conclusion, PA-TNA may improve the detection limits of low-abundance alleles using NGS.

Citing Articles

Extracellular vesicles in cancers: mechanisms, biomarkers, and therapeutic strategies.

Ma Y, Zhang X, Liu C, Zhao Y MedComm (2020). 2024; 5(12):e70009.

PMID: 39611045 PMC: 11604295. DOI: 10.1002/mco2.70009.


Exploring Optimal Biomarker Sources: A Comparative Analysis of Exosomes and Whole Plasma in Fasting and Non-Fasting Conditions for Liquid Biopsy Applications.

Nasu M, Khadka V, Jijiwa M, Kobayashi K, Deng Y Int J Mol Sci. 2024; 25(1).

PMID: 38203541 PMC: 10779159. DOI: 10.3390/ijms25010371.


Extracellular vesicle-based liquid biopsy biomarkers and their application in precision immuno-oncology.

Asleh K, Dery V, Taylor C, Davey M, Djeungoue-Petga M, Ouellette R Biomark Res. 2023; 11(1):99.

PMID: 37978566 PMC: 10655470. DOI: 10.1186/s40364-023-00540-2.


Small RNA sequencing analysis of peptide-affinity isolated plasma extracellular vesicles distinguishes pancreatic cancer patients from non-affected individuals.

Roy J, Wajnberg G, Ouellette A, Boucher J, Lacroix J, Chacko S Sci Rep. 2023; 13(1):9251.

PMID: 37286718 PMC: 10247738. DOI: 10.1038/s41598-023-36370-3.


Recent developments in isolating methods for exosomes.

Gao J, Li A, Hu J, Feng L, Liu L, Shen Z Front Bioeng Biotechnol. 2023; 10:1100892.

PMID: 36714629 PMC: 9879965. DOI: 10.3389/fbioe.2022.1100892.


References
1.
Mathai R, Vidya R, Reddy B, Thomas L, Udupa K, Kolesar J . Potential Utility of Liquid Biopsy as a Diagnostic and Prognostic Tool for the Assessment of Solid Tumors: Implications in the Precision Oncology. J Clin Med. 2019; 8(3). PMC: 6463095. DOI: 10.3390/jcm8030373. View

2.
Sorber L, Zwaenepoel K, Jacobs J, De Winne K, Goethals S, Reclusa P . Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation Protocol. Cancers (Basel). 2019; 11(4). PMC: 6521186. DOI: 10.3390/cancers11040458. View

3.
Wan Y, Liu B, Lei H, Zhang B, Wang Y, Huang H . Nanoscale extracellular vesicle-derived DNA is superior to circulating cell-free DNA for mutation detection in early-stage non-small-cell lung cancer. Ann Oncol. 2018; 29(12):2379-2383. PMC: 6311950. DOI: 10.1093/annonc/mdy458. View

4.
Luchini C, Veronese N, Nottegar A, Cappelletti V, Daidone M, Smith L . Liquid Biopsy as Surrogate for Tissue for Molecular Profiling in Pancreatic Cancer: A Meta-Analysis Towards Precision Medicine. Cancers (Basel). 2019; 11(8). PMC: 6721631. DOI: 10.3390/cancers11081152. View

5.
Leighl N, Page R, Raymond V, Daniel D, Divers S, Reckamp K . Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer. Clin Cancer Res. 2019; 25(15):4691-4700. DOI: 10.1158/1078-0432.CCR-19-0624. View